Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-31, Stock:NVS, The news for the past five days is as follows:
2018-07-24: NEWS1: Biogen Stock Trending Higher on Strong Q2 2018 Results.NEWS2: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS3: Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco.NEWS4: Novartis's Cultural Revolution Will Be AI-Enabled and Desk-Free.NEWS5: Novartis’s Key Developments in July.NEWS6: Novartis’s Q2 2018 Earnings: Alcon.NEWS7: The Swiss Stock Market Climbed On Bank Strength.NEWS8: The Swiss Stock Market Climbed On Bank Strength.NEWS9: Novartis’s Q2 2018 Earnings: Sandoz.NEWS10: J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018.
2018-07-25: NEWS1: Why AnaptysBio Rose 10.5% Today.NEWS2: Why AnaptysBio Rose 10.5% Today.NEWS3: Why AnaptysBio Rose 10.5% Today.NEWS4: Gilead's Earnings Fail to Impress.NEWS5: Glaxo (GSK) Beats on both Earnings and Revenue in Q2.NEWS6: Did This Top Biotech Stock Just Go on Sale?.NEWS7: Did This Top Biotech Stock Just Go on Sale?.NEWS8: The Swiss Stock Market Rose Slightly On Roche Strength.NEWS9: The Swiss Stock Market Rose Slightly On Roche Strength.NEWS10: Novartis’s Valuation after Its Q2 2018 Earnings.
2018-07-26: NEWS1: Wall Street Analysts Estimate a Decline in Sanofi’s Adjusted EPS in Q2.NEWS2: Could Sanofi’s Sales Decline Again in Q2 2018?.NEWS3: Celgene Raises Revenue Guidance after Solid Growth in Q2 2018.NEWS4: Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up.NEWS5: Glaxo (GSK) Q2 Earnings & Sales Beat Estimates, '18 View Up.NEWS6: Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit.NEWS7: Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit.NEWS8: The Swiss Stock Market Jumped On Broad Strength.NEWS9: The Swiss Stock Market Jumped On Broad Strength.NEWS10: Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities.NEWS11: Omeros Announces Voluntary Dismissal Of Infringement Suit Against Sandoz.NEWS12: Omeros Announces Voluntary Dismissal Of Infringement Suit Against Sandoz.NEWS13: Biotech Stocks Facing FDA Decision In August.NEWS14: Biotech Stocks Facing FDA Decision In August.
2018-07-27: NEWS1: Antibiotics market wipes out 80 jobs at Peninsula company a month after its 1st drug approval.NEWS2: 1 week until the deadline for Disrupt SF 2018’s Hackathon + new sponsor prizes.NEWS3: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS4: Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales.NEWS5: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS6: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS7: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS8: Incyte (INCY) to Report Q2 Earnings: What's in the Cards?.NEWS9: Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up.NEWS10: The Swiss Stock Market Logged Modest Gains - LafargeHolcim In Focus.NEWS11: The Swiss Stock Market Logged Modest Gains - LafargeHolcim In Focus.NEWS12: The Swiss Stock Market.NEWS13: The Swiss Stock Market.NEWS14: Novartis' Sandoz Gets European Commission Approval For Biosimilar Hyrimoz.NEWS15: Novartis' Sandoz Gets European Commission Approval For Biosimilar Hyrimoz.NEWS16: Novartis: Tafinlar + Mekinist Combination Gets Positive CHMP Opinion.NEWS17: Novartis: Tafinlar + Mekinist Combination Gets Positive CHMP Opinion.
2018-07-30: NEWS1: How Celgene’s Otezla and Abraxane Did in Q2 2018.NEWS2: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS3: What's in the Cards for Conatus (CNAT) This Earnings Season?.NEWS4: Novartis Reports EU Approval Of Aimovig - Quick Facts.NEWS5: Novartis Reports EU Approval Of Aimovig - Quick Facts.NEWS6: ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates.NEWS7: ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates.NEWS8: A Look at Celgene’s Financials in Q2 2018.NEWS9: A Look at Teva’s Earnings Estimates ahead of Q2 Results.NEWS10: Why Analysts Expect Teva’s Revenues to Fall in the Second Quarter.NEWS11: The Swiss Stock Market Dipped As Defensive Heavyweights Fall.NEWS12: The Swiss Stock Market Dipped As Defensive Heavyweights Fall.NEWS13: The Majority of Analysts Recommend a ‘Hold’ for Teva.NEWS14: The Swiss Stock Market.NEWS15: The Swiss Stock Market.NEWS16: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.NEWS17: European Medicines Agency's CHMP Says Yes To 7 Drugs, No To 1.

Answer: Rise